

What is claimed is:

1. Use of a composition comprising CD19-targeting engineered allogeneic CAR-T cells in the manufacture of a medicament for the treatment of an autoimmune disease associated with CD19-expressing B-cells, or the reduction of one or more symptoms of the autoimmune disease associated with CD19-expressing B-cells, the CD19-targeting engineered allogeneic CAR-T cells comprising:
an anti-CD-19 CAR, wherein the anti-CD19 CAR comprises single chain variable Fragment (scFv) of FMC63 antibody, a CD8 hinge, a CD8 transmembrane domain, a 4-1BB co-stimulatory domain and a CD3 zeta signaling domain, and wherein the CD19-targeting engineered allogeneic CAR-T cells further comprise an inactivated *PDCDI* gene.
2. The use of claim 1, wherein the anti-CD19 CAR is encoded by a nucleic acid integrated into the *TRAC*, *CBLB*, *PDCDI*, *CTLA-4*, *LAG3*, *Tim3*, *BILF1*, *BY55*, *TIGIT*, *B7H5*, *LAIR1*, *SIGLEC10*, or *2B4* gene.
3. The use of claim 1, wherein the CD19-targeting engineered allogeneic CAR-T cells further comprise an inactivated *TRAC* gene.
4. The use of claim 1, wherein the autoimmune disease is selected from a group consisting of: Systemic Lupus Erythematosus (SLE), Rheumatoid Arthritis (RA), Type 1 Diabetes (T1D), Sjögren's syndrome, and Multiple Sclerosis (MS).
5. The use of claim 1, wherein the one or more symptoms of the autoimmune disease is selected from the group consisting of proteinuria, alopecia, increased IgM and IgG antibody titers, the presence of anti-nucleoprotein IgG or IgM in blood serum, increased B cell counts in blood plasma, and the presence of skin lesions or discoloration.
6. The use of claim 1, wherein the anti-CD19 CAR is encoded by a nucleic acid comprising a coding sequence for the anti-CD19 CAR.

7. The use of claim 6, wherein the nucleic acid is integrated into the genome of the engineered immune cell and the integration of the nucleic acid coding for the anti-CD19 CAR is performed using a CRISPR nuclease and a nucleic acid-targeting nucleic acid (NATNA).
8. The use of claim 7, wherein nucleic acid encoding the anti-CD19 CAR is integrated into the *TRAC* gene.
9. The use of claim 8, wherein prior to the integration, the nucleic acid coding for the anti-CD19 CAR is delivered into the T cells via a viral vector.
10. The use of claim 1, wherein the medicament is formulated to comprise a dose of CD19-targeting engineered CAR-T cells equivalent to 1/1000 of the dose used to treat B cell malignancies with the CD19-targeting engineered CAR-T cells.
11. The use of claim 1, wherein the medicament is formulated to comprise a dose of between 10,000 and 100,000,000 of the CD19-targeting engineered CAR-T cells.
12. The use of claim 1, wherein the medicament is formulated for treatment of a patient that has undergone lymphodepletion by treatment with cyclophosphamide, fludarabine, azathioprine, methotrexate, mycophenolate, a calcineurin inhibitor, or voclosporin, or treatment with a combination of cyclophosphamide and fludarabine
13. Use of a composition in the manufacture of a medicament for the treatment of an autoimmune disease associated with CD19-expressing B-cells, the composition comprising CD19-targeting allogeneic engineered CAR-T cells expressing a CAR comprising single chain variable fragment (scFv) of FMC63 antibody, a CD8 hinge, a CD8 transmembrane domain, a 4-1BB co-stimulatory domain and a CD3 zeta signaling domain, and wherein the CAR-T cells further comprise an armoring genome modification comprising an inactivated *PDCD1* gene, the cells being in an amount equivalent to 1/1000 of the dose used to treat B cell malignancies with the CD19-targeting engineered CAR-T cells.

14. The use of claim 13, wherein the CD19-targeting allogeneic engineered CAR-T cells further comprise an inactivated *TRAC* gene.
15. The use of claim 13, wherein the CD19 CAR is encoded by a nucleic acid integrated into the *TRAC* gene.
16. The use of claim 13, wherein the autoimmune disease is selected from a group consisting of: Systemic Lupus Erythematosus (SLE), Rheumatoid Arthritis (RA), Type 1 Diabetes (T1D), Sjögren's syndrome, or Multiple Sclerosis (MS).
17. The use of claim 13, wherein the medicament comprises between 10,000 and 100,000 of the CD19-targeting engineered immune cells.
18. Use of composition in the manufacture of a medicament for the treatment of an autoimmune disease associated with CD19-expressing B-cells in a patient, the composition comprising engineered allogeneic immune cells expressing an anti-CD19 CAR comprising single chain variable fragment (scFv) of FMC63 antibody, a CD8 hinge, a CD8 transmembrane domain, a 4-1BB co-stimulatory domain, and a CD3 zeta signaling domain, wherein the immune cells have been assessed for *in vitro* activity against B cells, and wherein the engineered allogeneic immune cells expressing an anti-CD19 CAR further comprise an inactivated *PDCD1* gene.
19. The use of claim 18, wherein the engineered allogeneic immune cells expressing an anti-CD19 CAR further comprise an inactivated *TRAC* gene.
20. The use of claim 18, wherein the activity against B cells is assessed as cytotoxicity in co-culture with B cell comprising compositions selected from blood plasma, PBMC fraction, and a B cell fraction.
21. The use of claim 19, wherein the co-culture has an effector cell:target cell ratio between 1:10 and 10:1.
22. The use of claim 20, wherein the activity against B cells is assessed as reduction of antibody secretion by B cells.

23. The use of claim 22, wherein the reduction of antibody secretion is assessed by
- (a) measuring the total IgG concentration in a culture comprising B cells selected from blood plasma, PBMC fraction and a B cell fraction, or
 - (b) measuring the concentration of IgG characteristic of autoimmune disease in a culture comprising B cells selected from blood plasma, PBMC fraction and a B cell fraction.